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Because the mental retardation caused by some in-
born errors of metabolism is to a large degree pre-
ventable by appropriate and early therapy, considera-
tion is now being given to the possibility of mass 
screening for these disorders in the neonatal period. 
Experience with the prototype, the phenylketonuria 
(PKU) program, dictates that mass screening for in-
born errors of metabolism is here to stay and will 
most certainly expand in the future-like it or not. 
Since I have recently gained some insight into the field 
as Metabolic Consultant to the State Health Depart-
ment, I wish to review the PKU program in Virginia-
the many pitfalls in the diagnosis and treatment of this 
disorder, and the feasibility of mass or selective screen-
ing for other inborn errors. 
Mass Screening 
In 1966, Virginia passed a law making it mandatory 
to test all newborns for the presence of PKU; indeed, 
today most states have such a law. The State Health 
Department responded to the legislature's charge to 
implement the program by: 1) establishing accurate 
Guthrie testing in three State laboratories, 2) estab-
lishing a quantitative serum phenylalanine (PA) and 
tyrosine procedure at its central laboratory in Rich-
mond, and 3) providing nutritional and medical follow-
up for diagnosed cases. Three full years of experi-
ence with the program have demonstrated its worth 
not only financially, but also in the prevention of 
mental retardation. 
From the bookkeeping viewpoint, at $0.42 per test, 
97% of the 76,000 births in the State of Virginia last 
year were screened for about $31,000. At an incidence 
of one in 13,000 it thus costs approximately $6,000 to 
uncover one case; it costs another $2,000 to provide 
therapy. In contrast, the cost to the State for the 
lifetime institutional care of the invariably severely 
retarded and untreated PKU patient is, very conserva-
tively, $125,000. One state's estimate put it at twice 
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that figure. A recent review of the rolls of the State's 
institutions discloses 45 such PKU patients. At present 
we are actively treating 30 children at home, most 
of them diagnosed since the inception of the testing 
program. These compelling statistics should make 
believers of any nonbelievers regarding the financial 
soundness of the program. 
But we must soberly admit what this program hath 
wrought, especially in the way of need for a more 
precise diagnosis and long term follow-up of positively 
screened patients. In the classical phenylketonuric, with 
markedly deficient PA hydroxylase activity (Fig 1), 
the serum level will reach greater than 20 mg % 
by the second week and usually 30-40 mg % by 
the third week. 0-hydroxyphenylacetic acid usually ap-
pears in the urine when the serum phenylalanine level 
reaches 7 mg % , but phenyl pyruvic acid is not 
excreted in the urine until the serum phenylalanine 
reaches 13 to 15 mg % . Because this latter substance 
is what makes the ferric chloride test positive, it can 
be seen that urine tested under age 2-3 weeks might 
be negative despite a high blood level. It is for this 
reason that urinary screening gave way to blood 
screening via the Guthrie test. Of those who have 
a permanent elevation of serum PA (ie, greater than 
3-4 mg % ) , approximately % will follow this course 
where dietotherapy is necessary to allay mental re-
tardation (Berman et al, 1969). 
Because phenylalanine is an essential amino acid it 
cannot be completely eliminated from the diet; the 
aim therefore is to reach that amount of PA intake 
which will maintain the serum level between 3 and 7 
mg % (Berry and Wright, 1967). This amounts 
to approximately 1A, the normal intake, or 50-80 mg/ 
kg per day in early infancy and 20-40 mg/kg per day 
in older infants and children. Why maintain the serum 
level at 3-7 mg when the normal is 1-1.5 mg % ? 
If one aims for that normal level too much danger of 
undershooting exists, and PA deficiency is almost as 
deleterious to the developing infant as hyperphenylala-
ninemia. In fact, it has caused death in an occasional 
infant (Davens et al, 1965). Presently there is a co-. 
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operative study underway to determine if the 3-7 
mg % range might be relaxed to 10-12 mg % 
without deleterious effect, as there is no knowledge 
of what level correlates with injury to the developing 
central nervous system. These ranges of intake are 
only rough guidelines, and frequent monitoring of 
serum PA levels by Guthrie testing is required to de-
termine the more exact individual requirements. To 
make matters more difficult, these requirements often 
change with varying protein needs induced by infection, 
changes in the rate of growth, activity, etc. 
Variability of Phenylalanine and Protein Needs 
Of the 15 cases of phenylketonuria currently 
being followed in the MCV Metabolic Endocrine 
Clinic, I have selected two which demonstrate these 
extremely variable phenylalanine and protein needs. 
The first case (Fig 2) is that of a premature baby with 
a birth weight of 4 lb at 32 weeks gestation. The 
child was referred to MCV at age 3 weeks weighing 
3 lb 4 oz, and having a serum PA level of 38 mg 
% with a normal serum tyrosine and without 
detectable phenylpyruvic acid in the urine. Extreme 
lethargy, persistent vomiting, and abdominal disten-
sion were present on admission and were not ascrib-
able to other causes (ie, sepsis, organic bowel disease, 
etc), and might have been due to the high serum PA 
level. For this reason an extremely restricted PA in-
take of 16 mg/ kg per day was instituted and conse-
quent to the fall in the phenylalanine level, clinical 
symptoms disappeared and weight gain ensued. How-
ever, with a rapid weight gain the PA needs markedly 
increased and even intakes of 80-90 mg/kg per day 
did not suffice to maintain the serum PA level above 
2 mg % . For this reason it was thought that this 
case might merely be one of transient hyperphenylala-
ninemia and a full phenylalanine intake of 120 mg/ 
kg per day was offered in the form of regular milk. 
This resulted in a rise of serum phenylalanine to 22 
mg % . Therefore, an intake of 80-90 mg/ kg was 
again used with a consequent fall in the serum PA 
again to Jess than 2 mg % . Regular milk supply-
ing 160 mg/kg PA per day raised the level to 15 
mg %, and despite a drop in intake to 100-120 
mg/ kg per day, it continued to rise to 28 mg % . 
This time a decrease in intake to 80-90 mg/ kg brought 
the infant to the correct range. By this time the rate of 
growth had also slowed somewhat. Since discharge 
this child's serum PA level has been maintained between 
3-7 mg % on an even more reduced intake of 
50 mgjkg per day. This infant, then, with the catch-up 
growth typical of the premature, initially required con-
siderably more than the expected amount of dietary 
PA (90- 100 mg/ kg per day) . 
The second case is that of a 9 year old girl with an 
I.Q. of 85 who had findings in early infancy of 
classical PKU (Fig 3). She was maintained in fairly 
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Fig 1-The classical phenylketonuric with markedly de-
ficient PA hydroxylase activity. 
"° 100 
.. "' 
, o I 9.0 
''° t 
00 !. 
t 
30 80 ! 
i 
60 • 
~ ~ 
20 ! ,o 
20 
~ 
r 
T IME ( day1 ) 
Fig 2-The course of case one. 
. . 
· ----· ----------------------------t_ -_ '!. .... j \\/\/\ 
Jon. 
1%7 
Joo 
1966 
Fig 3-The course of case two. 
Jan. 
1%9 
Joo 
.,, 
,, 
r 
31 
SCREENING FOR INBORN ERRORS 
good control through the first five to six years at the 
usual intake of 20-30 mg/ kg of PA per day. There-
after, because almost all brain growth has occurred 
by this age and because by intelligence testing and 
gross observations there is no deterioration in func-
tion when the diet is discontinued, the phenylketonuric 
child is usually gradually introduced to a normal PA 
intake. However, one very recent careful study sug-
gests a measurable decrease of motor skills and 
learning processes may occur with a discontinuation 
of the diet at this age (Anderson et al , 1968) . Be-
cause of this study, because the mother and child were 
most comfortable with the diet, and because the 
mother was fearful of any possible deterioration, PA 
restriction was continued. However, for the past three 
years, despite a low dietary PA intake of 16 mg/kg per 
day, the serum PA has been no lower than 12 mg 
% . An increase in dietary intake of PA ( as natural 
food protein) to 24 mg/kg per day in December, 1969, 
merely caused an increase in the serum PA to 22 mg 
% . When the protein intake was increased in March, 
1970, from a suboptimal level of 0.7 gm/kg per day 
to 1.3 gm/ kg per day (by providing additional 
Lofenalac) , a lowering of the serum PA to 7 mg % 
was effected, despite a small increase in total PA 
intake. This child therefore had high serum PA 
for several years because tissue protein breakdown 
was occurring in the face of inadequate protein 
intake. The changing dietary needs demonstrated by 
these two cases emphasize the need for constant 
monitoring with medical and nutritional supervision 
on an individual basis. 
Other Causes of Hyperphenylalaninemia 
Other than classical PKU there are at least five to 
six additional causes of hyperphenylalaninemia. Ap-
proximately 2/ 1000 normal newborns have a posi-
tive Guthrie test in the screening program, but the 
vast majority are due to transient neonatal tyrosine-
mia. This entity is believed to be due to a delay in the 
maturation in the liver of the enzyme parahydroxy-
phenylpyruvic acid oxidase, and large amounts of 
parahydroxyphenylpyruvic acid are usually found in 
the urine. Secondarily, serum PA rises and gives the 
positive Guthrie test, but serum tyrosine is character-
istically much higher than phenylalanine. The values 
usually return to normal without therapy in one to 
two months, but occasionally not for six to eight 
months. No clinically apparent motor or intellectual 
deficits result from this transient defect and no treat-
ment is indicated. However, until the tyrosine levels 
return to normal it is impossible to be certain that the 
enzyme defect is not of a permanent nature, then 
called tyrosinosis ( or tyrosinemia). This disorder fre-
quently causes severe liver and kidney damage and 
early death. Because it is ameliorated by a low tyro-
sine diet it becomes imperative that neonatally ele-
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vated tyrosine levels picked up by pos1t1ve Guthrie 
tests be followed serially until they become normal. 
Another cause of hyperphenylalaninemia of a tran-
sient nature is a delay in the maturation of the en-
zyme PA hydroxylase where the infant initially has 
classical findings of PKU but later in infancy tolerates 
a normal phenylalanine intake without hyperphenyla-
laninemia. Because of this possibility the dietary re-
striction of all infants with what initially appears to 
be classical PKU should be relaxed periodically to 
demonstrate persistence of the defect, as was done in 
my first example. 
Of the approximate 1/:i of infants with permanent 
hyperphenylalaninemia who do not have the classical 
course of PKU, we encounter two generally described 
types. One is called atypical PKU, where levels of 
greater than 20 mg % are not associated with mental 
retardation despite there being no treatment. These 
children are usually uncovered as an older sibling of 
a newly diagnosed case from the screening program. 
The other term, simply hyperphenylalaninemia, is ap-
plied when the serum PA level never rises above 20 
mg % without dietary restrictions and is usually not 
associated with mental retardation. The PA tolerance 
tests unfortunately do not distinguish these groups 
from the classical PKU patient, but there is some evi-
dence to suggest that the absence in the urine of the 
breakdown products of PA, namely phenyl pyruvic acid 
and orthohydroxyphenylpyruvic acid, favors a diagno-
sis of one of these milder forms of the disease. Indeed, 
some qualified investigators recommend not treating 
an infant unless there are PA metabolites in the urine, 
no matter how high the level of serum PA. It is there-
fore clear that we may be unnecessarily treating, with 
inherent dangers, as many as 1/:i of patients thought to 
have classical PKU. There is obviously a need for bet-
ter means of diagnosing these subgroups. 
Finally, there is the rare infant who lacks the en-
zyme phenylalanine transaminase but who only has 
hyperphenylalaninemia when on a higher than normal 
PA intake. In this instance, of course, no phenyl pyru-
vic acid or orthohydroxyphenylpyruvic acid appears 
in the urine. Space does not permit a more detailed 
discussion of these variants, but I have mentioned them 
to emphasize that whereas just five years ago hyper-
phenylalaninemia was thought to be a simple disease 
state, mass screening has disclosed a wide spectrum 
of clinical and biochemical presentations with vari-
able prognoses and treatment. 
Indications for Screening 
With some of the machinery already established, 
the next logical question deals with what other inborn 
errors should be screened. To answer this it would be 
best at this point to review the ten principles of early 
detection outlined by a World Health Organization 
team a few years ago (Wilson and Junger, 1968) . It 
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will be seen that by these criteria the PKU program is a 
valid one: 
1 ) "The condition should be an important prob-
lem." Although not terribly common, PKU 
is important as it is a treatable cause of men-
tal retardation. 
2) "There should be an accepted treatment for 
patients with recognized disease." There is for 
PKU. For other aminoacidopathies it is not 
so well worked out-for galactosemia, to be 
mentioned shortly, there is an accepted treat-
ment. 
3) "Facilities for diagnosis and treatment should 
be available." These do exist but are most 
marginally funded, so that the more detailed 
work-ups required with increasing awareness 
of the heterogeneity of the disease are not pos-
sible. This will be a drawback to establishing 
other mass or selective screening programs. 
4) "There should be a recognizable latent or early 
symptomatic state." In the instance of PKU 
this is hyperphenylalaninemia, but at best 
this is likely an early symptomatic stage. Even 
dietary therapy instituted at less than 2 months 
of age results in only a mean I.Q. of 85 ± 12 
vs. the unaffected sibling comparison of I.Q. of 
TABLE 
Urinary Screening Tests for Metabolic Defects 
Disease FeCl, 
I. Phenylketonuria Green 
2. Maple Syrup Navy Blue 
3. Tyrosinosis Trans. Green 
4. Histidinemia Green 
5. Hyperglycinemia 
6. Fructose Into!. 
7. Galactosemia 
8. Cystinuria 
9. Homocystinuria 
10. Hurler's 
11. Morquio-Ullrich's 
12. Fanconi's ± 
13. Alkaptonuria Brown 
14. Lowe's 
15. Hyperlysinemia 
DNPH 
C- N 
C-TAB 
± 
dinitrophenylhydrazine 
cyanide nitroprusside 
cetyl trimethylammonium bromide 
sometimes positive 
DNPH 
+++ 
+++ 
+++ 
++ 
+++ 
±(?) 
± 
+ 
+ 
109 ± 11. Whether the treatment is started too 
late or is inadequate is not known. 
5) "There should be a suitable test or examina-
tion." The Guthrie test fits this bill well. 
6) "The test should be acceptable to the popula-
tion." The Guthrie test again fits this bill well. 
7) "The natural history of the condition, including 
the development from latent to declared dis-
ease should be adequately understood." Clas-
sical PKU qualifies to a good degree, although 
what level of PA or its metabolites is actually 
injurious is not yet known-nor is it known 
why some patients with significant elevations of 
serum PA do not develop retardation, as in 
atypical phenylketonuria. 
8) "There should be an agreed policy on whom to 
treat as patients." We are in the same trouble 
here with PKU because, as mentioned earlier, 
some physicians would delay treatment until 
metabolic products in the urine appear. Some 
use the level of 15 and others 20 mg % before 
starting treatment. 
9) "The cost of case finding should be economically 
balanced in relation to possible expenditure on 
medical care as a whole." As pointed out, PKU 
scores high here. 
C- N Benedict's C-TAB 
± 
++ 
++ 
++ 
++ 
++ 
± 
± + 
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10) "Case finding should be a continuing process 
and not a once and for all project." This is 
certainly true for PKU. 
On the basis of these criteria, what other inborn 
errors would qualify for mass screening? Most amino-
acidopathies probably do not qualify at this time 
mainly because of their rarity and of the expensive 
chromatographic techniques required, making case-
finding too costly. Reduction in cost of detection 
might be achieved by the application of the bac-
terial "inhibition assay" technique as used in the Gu-
thrie test. In this procedure the excessive leucine of 
maple syrup urine disease prevents the inhibition of 
B. subtilis by 2-methyl leucine, and excessive histidine 
of histidinemia prevents inhibition of B. subtilis by 
azaserine. With more refined resins and increased 
automation, quantification by ion-exchange chroma-
tography might be a useful tool for mass screening of 
aminoacidopathies, but this development is several 
years away. In the meantime pilot studies in special-
ized centers are proceeding, using one or two di-
mensional paper or thin layer chromatography, or 
high voltage electrophoresis as screening tools. In 
this way more knowledge of these rare diseases and 
their treatment can be obtained and we can then 
better satisfy criteria 2, 7, and 8, listed above. One 
such recent study (Clow, Saiver and Davies, 1969) of 
the plasma of over 36,000 neonates revealed 316 
with hyperaminoacidemia, but all except six were only 
transient. Five of the six permanent elevations were 
hyperphenylalaninemias and one was a case of hyper-
methionemia. 
Considerations are somewhat different concerning 
the disorder of carbohydrate metabolism, galactose-
mia. In this disorder a buildup in the blood and tissues 
of galactose and galactose-1-phosphate causes mental 
retardation, cataracts, liver and kidney disease, and 
usually early death. Whereas previous estimates have 
put the incidence at 1: 50,000, recent mass screening 
surveys put it at between 1: 20,000 to 1: 30,000 
(Hansen, 1969). Various screening tests are presently 
being evaluated-measuring either blood galactose 
levels via a bacterial inhibition assay technique or the 
actual levels of the deficient enzyme, galactose-1-
phosphate uridyl transferase, from spotted filter paper 
or with 50 microliters of heparinized blood. As for 
phenylketonuria and maybe for most inborn errors, it 
has already been established that there are several 
variants of galactosemia-four at present. It is not 
totally clear which types re·quire therapy, but because 
this disease satisfies most of the established prin-
ciples, with good treatment available (lactose elimina-
tion) it would appear that as soon as it is determined 
which test is most suitable, it will be the next meta-
bolic disorder to be mass screened. Indeed one state 
has already made testing for galactosemia mandatory 
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and several other states are seriously considering it. 
There are a host of other inborn metabolic disor-
ders for which diagnostic tests are available, but 
their consideration for inclusion in mass screening are 
not as pressing as the aforementioned diseases, either 
because of their rarity (Wilson's disease), the lack of 
adequate therapy, or the lack of a test acceptable to 
the population ( cystic fibrosis) . 
Selective Screening 
Though to this point we have been talking about 
mass screening, I would like to discuss one type of 
selective screening-that is, the screening of a selected 
group. Mental retardates, specifically, are more likely 
to have metabolic disorders than the general popula-
tion. At first blush it would seem to be a waste of time, 
effort, and money to seek a diagnosis once mental re-
tardation has already ensued, because in almost all 
instances therapy cannot reverse this damage. On the 
other hand, several other considerations point out the 
validity of testing mental retardates for metabolic dis-
orders. 
1) Establishing the cause of retardation enables 
better prognosticating and genetic counsel-
ling. 
2) If therapy is started early with only mild re-
tardation present, further deterioration might 
be prevented or slowed. 
3) Identifying the inborn error allows a better 
determination of its incidence and therefore 
its possible worthiness for inclusion in mass 
screening programs. 
4) Identifying the inborn error may give more 
insight into the various modes of clinical 
and/ or biochemical presentation and there-
fore allow earlier recognition of future cases 
and determination of appropriate therapy. 
There are almost as many screening tests as there 
are inborn errors of metabolism, but by selecting a 
few tests that will identify several different disorders, 
a workable screening panel can be established. The 
table depicts such a panel of tests established initially 
by R. B. Young (Department of Pediatrics, Medical 
College of Virginia) and continued presently by myself 
as a service to physicians in the State. In the present 
practice, fresh acidified urine of any patient with sus-
pected mental retardation, or with a clinical complex 
to suggest an inborn error, is mailed to the Pediatric 
Metabolism Laboratory at the Medical College of Vir-
ginia. These tests are performed once weekly and the 
results mailed promptly to the referring physician. 
With more experience with these programs, it is ex-
pected that these tests will have to be modified ( as bas 
recently been found to be the case for the cyanide 
nitroprusside and C-T AB tests) , and others added. 
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Summary 
I have briefly outlined the PKU program in the 
State of Virginia and tried to demonstrate how this 
screening experience has disclosed the heterogeneity 
of the disease plus the need for an individualized ap-
proach to dietary control. I have applied the principles 
of mass screening to examine the feasibility of testing 
for other inborn errors and, on this basis, feel that 
galactosemia will soon next join with PKU. Mass 
screening for other aminoacidopathies will await more 
refined testing techniques and a definition of their 
incidence and mode of therapy. In the meantime, 
accumulated experience thus far mandates the estab-
lishment of specialized lab facilities and multidisci-
plinary teams; these will be necessary to effect opti-
mal evaluation and treatment of patients found to be 
positive by these screening techniques. 
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